IN 2019, DAMON RUNYON SCIENTISTS PURSUED BRAVE AND BOLD CANCER RESEARCH THAT IS LEADING TO NEW TREATMENTS, EARLIER DIAGNOSIS AND PREVENTION—TO SAVE LIVES.

THIS YEAR ALONE, DAMON RUNYON SCIENTISTS

- Developed armored CAR (chimeric antigen receptor) T cells to deliver cancer-killing molecules to brain tumors.
- Created a new cancer vaccine that activates the immune system to fight tumors throughout the body.
- Used cutting-edge imaging technology to discover that the distribution of immune cells within breast cancer tumors is predictive of survival.
- Uncovered how E. coli bacteria in the gut produce toxins that cause mutations in cells, which may result in therapies for the prevention and treatment of some colon cancers.

AWARDS AND HONORS

Damon Runyon alumnas were elected to the National Academy of Sciences (the science “Hall of Fame”): Karla A. Kirkegaard, PhD; Dianne K. Newman, PhD; Elaine A. Ostrander, PhD; Cynthia Wolberger, PhD; Mariana F. Wolfner, PhD. Alumni elected to the prestigious National Academy of Medicine are Edwin G. Abel, PhD; Julie A. Segre, PhD; Catherine J. Wu, MD.

Former Fellow Bruce W. Stillman, PhD, shared the Gairdner Award for pioneering research on eukaryotic DNA replication cycles and responses to DNA damage.

Former Damon Runyon Fellow and Board Member Elaine V. Fuchs, PhD, and Former Fellow and Nobel Laureate James E. Rothman, PhD, were elected foreign members of the Royal Society of the United Kingdom.

Former Damon Runyon Fellow H. Michael Shepard, PhD, shared the prize for the Lasker-DeBakey Clinical Medical Research Award, and Former Damon Runyon Grantee Jacques F.A.P. Miller, PhD, shared the Albert Lasker Basic Medical Research Award. The Lasker Awards are among the highest international honors in medical research.

Former Innovator Emily P. Balskus, PhD, received the National Blavatnik Award for Young Scientists for deciphering the chemical role of the gut microbiome in human health.

Damon Runyon Board Member William G. Kaelin, Jr., MD, shared the Nobel Prize in Physiology or Medicine for discoveries of how cells sense and adapt to oxygen availability.
OUR MISSION
At the Damon Runyon Cancer Research Foundation, we fund high-risk, high-reward cancer research. We identify and enable young scientists who are brilliant, brave and bold enough to go where others haven’t.

RESEARCH PROGRAMS
• We are currently funding 212 researchers at 57 institutions across the nation.
• In fiscal year 2019, we awarded nearly $20 million in new grants to 66 exceptional scientists.

FINANCIAL INFORMATION

TOTAL REVENUE: $26 MILLION
- Investment Return 51.9%
- Contributions 40.9%
- Misc. Income 4.3%
- Bequests & Trusts 1.5%
- Damon Runyon Broadway Tickets 1.4%

TOTAL EXPENSES: $26 MILLION
- Award Programs 85.4%
- Fundraising 11.6%
- General Administration 3.0%

100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.
We pay our low overhead with revenue from Damon Runyon Broadway Tickets and our endowment.